Biomarker testing in patients diagnosed with advanced/metastatic medullary thyroid cancer in the USA.

IF 1.7 4区医学 Q3 PHARMACOLOGY & PHARMACY

Personalized medicine Pub Date : 2023-03-01 DOI:10.2217/pme-2022-0050

Naleen Raj Bhandari, Lisa M Hess, Rohan C Parikh, Anthony N Sireci, Peter M Krein, James A Kaye

{"title":"Biomarker testing in patients diagnosed with advanced/metastatic medullary thyroid cancer in the USA.","authors":"Naleen Raj Bhandari, Lisa M Hess, Rohan C Parikh, Anthony N Sireci, Peter M Krein, James A Kaye","doi":"10.2217/pme-2022-0050","DOIUrl":null,"url":null,"abstract":"Aim: To describe real-world testing patterns for RET in US patients with advanced/metastatic medullary thyroid cancer and determine consistency of real-world testing practices with national guidelines. Materials & methods: The authors performed a retrospective medical record analysis of patients with advanced/metastatic medullary thyroid cancer who initiated systemic therapy between 2013 and 2018. Seventy-five US-based oncologists collected the data using a customized electronic data collection form. Results: A total of 59.6% (121 of 203) of patients underwent testing for RET, and 37.2% (45 of 121) had a RET mutation, of which 55.6% were identified as RET mutation-positive before initial diagnosis. Overall, 90 (44.3%) patients were tested for biomarkers on or after initial diagnosis, with RET being the most tested (95.6%) biomarker. Conclusion: The authors' findings suggest an opportunity to improve testing rates in accordance with treatment guidelines.","PeriodicalId":19753,"journal":{"name":"Personalized medicine","volume":"20 2","pages":"131-142"},"PeriodicalIF":1.7000,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Personalized medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2217/pme-2022-0050","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Aim: To describe real-world testing patterns for RET in US patients with advanced/metastatic medullary thyroid cancer and determine consistency of real-world testing practices with national guidelines. Materials & methods: The authors performed a retrospective medical record analysis of patients with advanced/metastatic medullary thyroid cancer who initiated systemic therapy between 2013 and 2018. Seventy-five US-based oncologists collected the data using a customized electronic data collection form. Results: A total of 59.6% (121 of 203) of patients underwent testing for RET, and 37.2% (45 of 121) had a RET mutation, of which 55.6% were identified as RET mutation-positive before initial diagnosis. Overall, 90 (44.3%) patients were tested for biomarkers on or after initial diagnosis, with RET being the most tested (95.6%) biomarker. Conclusion: The authors' findings suggest an opportunity to improve testing rates in accordance with treatment guidelines.

查看原文本刊更多论文

美国晚期/转移性甲状腺髓样癌患者的生物标志物检测

目的:描述美国晚期/转移性甲状腺髓样癌患者RET的实际检测模式，并确定实际检测实践与国家指南的一致性。材料和方法:作者对2013年至2018年间开始全身治疗的晚期/转移性甲状腺髓样癌患者进行了回顾性医疗记录分析。75名美国肿瘤学家使用定制的电子数据收集表格收集数据。结果:203例患者中有121例(59.6%)接受了RET检测，其中有45例(37.2%)存在RET突变，其中55.6%的患者在初诊前RET突变阳性。总体而言，90例(44.3%)患者在初次诊断时或之后进行了生物标志物检测，RET是检测最多的(95.6%)生物标志物。结论:作者的发现提示了根据治疗指南提高检测率的机会。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Personalized medicine 医学-药学

CiteScore

3.30

自引率

4.30%

发文量

审稿时长

6-12 weeks

期刊介绍： Personalized Medicine (ISSN 1741-0541) translates recent genomic, genetic and proteomic advances into the clinical context. The journal provides an integrated forum for all players involved - academic and clinical researchers, pharmaceutical companies, regulatory authorities, healthcare management organizations, patient organizations and others in the healthcare community. Personalized Medicine assists these parties to shape thefuture of medicine by providing a platform for expert commentary and analysis. The journal addresses scientific, commercial and policy issues in the field of precision medicine and includes news and views, current awareness regarding new biomarkers, concise commentary and analysis, reports from the conference circuit and full review articles.